CPI-300 is a 450 mg single dose, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL.
IntelGenx president and CEO Horst Zerbe said they believe physicians will embrace CPI-300 as a more convenient and safe alternative for their patients requiring high-dose anti-depressant therapy.
"So we now turn our focus towards the commercialization of CPI-300, with the objective of a product launch with a partner by the second quarter of 2012," Zerbe said.